Life expectancy has increased substantially for people in the United States with Down syndrome, from a median age of 4 years old in the 1950s to 57 years old in 2019.
argenx wins EMA CHMP nod for subcutaneous Vyvgart in myasthenia gravis – Pharmaceutical Technology
Vyvgart is argenx’s high-grossing drug, having generated $269m in Q2 2023. Image Credit: Kateryna Kon / Shutterstock. The Committee for Medicinal Products for Human Use